Analyzing data in the 2024 Springfield fire report
One significant achievement in 2024 was the completion and opening of the newly reconstructed Fire Station 7. This state-of-the-art facility was made possible by voter-approved funding and was designed with firefighter health and safety in mind, improving efficiency and emergency response times, according to a news release.
The annual report cites several facts from SFD's year in 2024:
40,424 instructional hours were delivered to 634 students
185 leave-behind naloxone kits (which can treat narcotic overdoses in an emergency situation) were distributed by firefighters in 2024
SFD firefighters visited 5,440 homes and installed 1,436 smoke alarms
34 structure fire investigations led to felony charges in 11 fires
Only 153 structure fires and 41 vacant structure fires were reported.
Compared to previous year's data, there was a decrease in yearly opioid incidents. The year of 2024 saw 122 incidents, compared to a peak of 463 incidents recorded in 2021.
However, fire calls were up when compared; 940 in 2024, and 886 in 2023.
'Community Risk Reduction remains a cornerstone of our mission,' said Fire Chief David Pennington in the release. 'Through our Project RED Zone initiative, we engaged thousands of households, installed hundreds of smoke alarms and provided critical fire safety education.'
Pennington said the SFD expanded its outreach efforts with fire and life safety programs, community CPR and AED training, and senior fire safety initiatives, ensuring that residents of all ages have the knowledge and tools to prevent fires and emergencies.
'Our continued naloxone distribution program, with leave-behind kits, played a vital role in public health and harm reduction, increasing bystander intervention and saving lives in opioid overdose incidents,' Pennington said.
Read the full SFD 2024 annual report here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Shaker Heights cheerleader released from hospital weeks after leg amputation
SHAKER HEIGHTS, Ohio (WJW) – The Shaker Heights cheerleader whose leg needed to be amputated after an unthinkable diagnosis celebrated a big milestone on Friday. Amani Smith was released from Rainbow Babies and Children's Hospital, weeks after doctors were forced to amputate her left leg. Amani and her family are thrilled to finally be home, but her major life change is only just beginning. The 17-year-old was at cheerleading camp earlier this summer when she started complaining about a stomach ache. Within hours, she was rushed into emergency surgery. Bernie Kosar not giving up as he waits on liver transplant Doctors at the time discovered a ruptured abdominal cyst and an infection led to sepsis, a potentially deadly condition. She had a stroke during surgery and her parents said a nicked artery during the procedure cut off blood flow to her left leg for hours. Doctors were forced to amputate and she was placed on life support for nearly a week. Now, Amani has recovered enough to return home and her family is navigating the next steps as she is determined to dance again. Big Cleveland weekend: What to know about all the events All the while, the Shaker Heights community has rallied around the family. 'It feels really good. I have a good support group around me,' Amani said. 'After two months and a few days, I'm finally free.' Amani is going into her senior year of high school. So far, a GoFundMe page has raised more than $37,000 for the family, who hopes to get her a prosthetic leg. Learn how to donate right here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Business Wire
10 hours ago
- Business Wire
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. 'The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities,' said TNF President and Chief Medical Officer, Mitchell Glass, M.D. 'We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage.' The improvements in the Company's financial position will be reflected in future financial statements of the Company. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Business Wire
11 hours ago
- Business Wire
QT Imaging Holdings Announces Results of First Annual Stockholder Meeting
NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. ('QT Imaging' or the 'Company') (OTCQB: QTIH), a medical device company engaged in the research, development, and commercialization of innovative body imaging systems, announced today that at the Annual Meeting of Company's stockholders (the 'Annual Meeting') held on August 19, 2025, the Company's stockholders voted to approve (i) the election of Daniel Dickson and James Greene as Class I directors to serve until the Company's 2028 Annual Meeting of Stockholders or until their respective successors are elected and qualified, (ii) the appointment of BPM LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 and (iii) an amendment to the Company's Second Amended and Restated Certificate of Incorporation to effect a reverse stock split at a specific ratio within a range of 2:1 to 20:1 to be fixed by the Company's Board of Directors. The Company plans to file the results of the Annual Meeting, as tabulated by an independent inspector of elections, on Form 8-K with the Securities and Exchange Commission today. About QT Imaging Holdings, Inc. QT Imaging is a public medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. For more information on the Company, please visit the company's website at
